UDG Healthcare

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services. It is listed on the London Stock Exchange. It is a constituent of the FTSE 250 Index.

UDG Healthcare plc
TypePublic
LSE: UDG
IndustryPharmaceutical
Founded1948 (1948)
HeadquartersDublin, Ireland
Key people
Peter Gray, Chairman
Brendan McAtamney, CEO[1]
Revenue€1,298.5 million (2019)[2]
€120.3 million (2019)[2]
€57.5 million (2019)[2]
Number of employees
8,700 (2019)[3]
Websitewww.udghealthcare.com

History

The company was established in Ballina in County Mayo as The United Drug Chemical Company, a co-operative controlled by Irish pharmacists, in 1948.[4] UDG bought Leicestershire-based Ashfield commercial and medical services for £12 million in 2000: Ashfield, a contract sales outsourcing firm serving pharmaceutical companies, had 400 employees at the time it was acquired.

In January 2007, the company acquired Presearch, a UK laboratory services company, for GBP £2.9 million.[5] It acquired Pharmexx, a Frankfurt-based business, in July 2012.[6] In September 2012 it decided to move its primary listing from Irish Stock Exchange to the London Stock Exchange.[7] It changed its name from United Drug to UDG Healthcare in October 2013.[8] In February 2014, the company made its largest acquisition when it bought KnowledgePoint360 which specializes in healthcare communications for €105 million and made it part of its Ashfield division.[9][10]

In September 2015, UDG Healthcare sold its Irish drug distribution businesses to McKesson Corporation for $466 million.[11] In May 2016 UDG Healthcare acquired Pegasus, an integrated healthcare communications consultancy.[12] In October 2016 the company acquired STEM Marketing, a provider of commercial, marketing and medical audits to pharmaceutical companies.[13] In July 2017, the company acquired Vynamic; later in the same month it acquired Cambridge BioMarketing for up to $35 million.[14] In August 2018, UDG Healthcare announced the sale of its Aquilant division to H2 Equity Partners, a European private equity firm, for a total potential net consideration of up to €23 million (approximately $27 million).[15]

Operations

UDG Healthcare plc operates across two divisions: Ashfield and Sharp.[16]

References
  1. Michael Cogley (3 February 2016). "UDG boss Fitzgerald steps down from €2.5m-a-year role". Independent.ie. Retrieved 2016-07-31.
  2. "Annual Results 2019". UDG Healthcare. Retrieved 5 March 2020.
  3. "At a glance". UDG Healthcare. Retrieved 20 March 2019.
  4. "Interview: Brendan McAtamney – CEO, UDG Healthcare, Ireland". Pharma Boardroom. 17 February 2017. Retrieved 5 March 2020.
  5. "United Drug buy UK lab distributor for £2.9m". RTÉ News. January 26, 2007.
  6. United Drug snaps up Pharmexx Irish Times, 26 July 2012
  7. United Drug set to shift to LSE FT, 5 September 2012
  8. United Drug: Yes to name change Irish Examiner, 10 August 2013
  9. UPDATE 2-UDG raises earnings growth forecast, sees deal paying off, Reuters.com (14 May 2014)
  10. UDG Healthcare invests €105m to expand communications unit The Irish Times, 27 February 2014
  11. Roshni Menon (18 September 2015). "UDG Healthcare to sell two units to McKesson for $466 million". Reuters.com. Retrieved 2016-07-31.
  12. "Healthcare Group UDG buys UK's second largest PR firm Pegasus for £16.8 million". 19 May 2016. Retrieved 28 April 2017.
  13. "UDG Healthcare acquires STEM Marketing for £84m". PM Live. 21 October 2016. Retrieved 28 April 2017.
  14. "Rare disease agency Cambridge Bio goes global with $35M buyout by Irish UDG - FiercePharma". www.FiercePharma.com. Retrieved 22 January 2018.
  15. "UDG Healthcare sells non-core Aquilant division and reviews Ashfield business". 8 August 2018. Retrieved 14 November 2018.
  16. "Sharp Packaging Services, a division of UDG Healthcare plc, announces capacity expansion in the US and UK". FT. 3 April 2017. Retrieved 28 April 2017.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.